ClinicalTrials.gg

Program

ralmitaront

Also written as “RO6889450” and “Ralmitaront”.

Its studies are mostly in Schizophrenia, led by Hoffmann-La Roche.

Furthest: phase 2, since Sep 12, 20184 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche40 open or runningphase 2since Sep 12, 2018Feb 23, 2016none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2016First study: phase 1 study in Healthy VolunteerFirst studyNCT02699372 · 164 enrolled · Netherlands
  2. Sep 12, 2018Phase 2 study in SchizophreniaNCT03669640 · 131 enrolled · United States, Japan, Spain and more
  3. Aug 12, 2020Phase 2 study in SchizophreniaNCT04512066 · 287 enrolled · United States, Japan, Russian Federation and more
  4. Mar 11, 2025Phase 1 study in SchizophreniaNCT06880328 · 35 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06880328Schizophrenia · United States1CompletedSep 4, 201935
NCT04512066Schizophrenia · United States, Japan, Russian Federation and more2CompletedJun 21, 2022287
NCT03669640Schizophrenia · United States, Japan, Spain and more2TerminatedMar 12, 2023131
NCT02699372Healthy Volunteer · Netherlands1CompletedApr 14, 2017164

How it is read

Names in the registry

  • “RO6889450”, 3 entries
  • “Ralmitaront”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.